Cue Biopharma, Inc. (CUE) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -101.17%.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -31.3 | -0.74 | 15.82 | 0.00 | - |
| 2017 | -10.3 | -0.05 | 3.90 | 0.00 | - |
| 2018 | -2.4 | -0.03 | 2.79 | 82.82 | - |
| 2019 | -9.5 | 0.66 | 6.41 | 101.18 | - |
| 2020 | -8.0 | 1.33 | 4.55 | 113.78 | - |
| 2021 | -8.0 | 0.83 | 5.40 | 23.68 | - |
| 2022 | -1.9 | -0.34 | 1.55 | 81.61 | - |
| 2023 | -2.4 | 0.09 | 3.26 | 22.00 | - |
| 2024 | -1.5 | 0.04 | 3.51 | 6.61 | - |
| 2025 | -1.1 | 0.02 | 1.09 | 1.05 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.37 | $0.00 | $-7.66M | - |
| 2017 | $-1.13 | $0.00 | $-23.23M | - |
| 2018 | $-1.94 | $1.14M | $-38.98M | -3411.5% |
| 2019 | $-1.66 | $3.46M | $-36.7M | -1061.2% |
| 2020 | $-1.56 | $3.15M | $-44.78M | -1419.8% |
| 2021 | $-1.41 | $14.94M | $-44.16M | -295.6% |
| 2022 | $-1.48 | $1.25M | $-52.8M | -4239.9% |
| 2023 | $-1.11 | $5.49M | $-50.73M | -924.1% |
| 2024 | $-0.72 | $9.29M | $-40.67M | -438% |
| 2025 | $-0.28 | $27.47M | $-26.6M | -96.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.58 | $-0.58 – $-0.58 | $1M | $1M – $1M | 1 |
| 2027 | $-0.60 | $-0.60 – $-0.60 | $1M | $1M – $1M | 1 |
| 2028 | $-0.51 | $-0.51 – $-0.51 | $1M | $1M – $1M | 1 |
| 2029 | $-0.52 | $-0.52 – $-0.52 | $1M | $1M – $1M | 1 |
